David, & all -- Oxbow may be silent, but the Globe & Mail trumpets on. There was another article on the 12th of April and one today, April 14, on the horrors of disease that will not respect the major pharmaceutical firms, not to mention their pathetic antibiotics.
O157 is mentioned. Synsorb is not.
For those who know and believe in this tide of VRE and MRS, not to mention deadly necrotizing fascitis(!), the few firms who are leaders in alternatives (mbi, syb) will be more attractive. Synsorb could easily build on the articles and interest; but why should they? The stock is drifting down, it is a chance to buy back shares sold at the top. Syb does not need more cash right now at their burn rate.
Time enough to do hype when you need cash.
Synsorb is the great hope for us all in GI diseases, that kill by toxins-- MBI is esteemed, but expected to be only a stopgap --synsorb and any others that use 'physical' actions rather than a chemical 'allopathy' or fighting the microorganisms, will prevail. Homeopathy is probably ridiculous.
Too bad Synsorb techniques couldn't be adapted to neutralize necrotizing fascitis... guess that is a silly idea -- n.f. victims don't die of toxins, do they? |
